4.7 Article

Cost-effectiveness analysis of COVID-19 screening strategy under China's dynamic zero-case policy

Journal

FRONTIERS IN PUBLIC HEALTH
Volume 11, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fpubh.2023.1099116

Keywords

COVID-19; cost-effectiveness; screening strategy; agent-based model; dynamic zero-case policy; China

Ask authors/readers for more resources

This study used cost-effectiveness analysis to optimize COVID-19 screening strategies under China's dynamic zero-case policy. Nine screening strategies with different screening frequencies and combinations of detection methods were designed. A stochastic agent-based model simulated the progress of the COVID-19 outbreak in two scenarios. The results showed that high-frequency screening is cost-effective and can help contain the spread of the epidemic under China's COVID-19 dynamic zero-case policy. Mass antigen testing is not cost-effective compared to mass nucleic acid testing, and using AT as a supplemental screening tool is more cost-effective when NAT capacity is insufficient or when outbreaks are spreading rapidly.
This study aims to optimize the COVID-19 screening strategies under China's dynamic zero-case policy through cost-effectiveness analysis. A total of 9 screening strategies with different screening frequencies and combinations of detection methods were designed. A stochastic agent-based model was used to simulate the progress of the COVID-19 outbreak in scenario I (close contacts were promptly quarantined) and scenario II (close contacts were not promptly quarantined). The primary outcomes included the number of infections, number of close contacts, number of deaths, the duration of the epidemic, and duration of movement restriction. Net monetary benefit (NMB) and the incremental cost-benefit ratio were used to compare the cost-effectiveness of different screening strategies. The results indicated that under China's COVID-19 dynamic zero-case policy, high-frequency screening can help contain the spread of the epidemic, reduce the size and burden of the epidemic, and is cost-effective. Mass antigen testing is not cost-effective compared with mass nucleic acid testing in the same screening frequency. It would be more cost-effective to use AT as a supplemental screening tool when NAT capacity is insufficient or when outbreaks are spreading very rapidly.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available